"10.1371_journal.pone.0141436","plos one","2015-11-25T00:00:00Z","Emily M Eichenberger; Joshua T Thaden; Batu Sharma-Kuinkel; Lawrence P Park; Thomas H Rude; Felicia Ruffin; Nina J Hos; Harald Seifert; Siegbert Rieg; Winfried V Kern; Steven K Lower; Vance G Fowler; Achim J Kaasch","Division of Infectious Diseases & International Health, Department of Medicine, Duke University School of Medicine, Durham, NC 27710, United States of America; Duke Global Health Institute, Duke University, Durham, NC 27710, United States of America; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Goldenfelsstraße 19-21, 50935 Cologne, Germany; German Centre for Infection Research (DZIF), Bonn-Cologne, University of Cologne, Albertus-Magnus-Platz, 50923 Cologne, Germany; Division of Infectious Diseases, Department of Medicine II, University Medical Center Freiburg, Hugstetter Straße 55, 79106 Freiburg, Germany; Division of Natural and Mathematical Sciences, Ohio State University, Columbus, OH 43210, United States of America","Conceived and designed the experiments: EME BSK VGF AJK SKL JTT. Performed the experiments: EME BSK THR JTT. Analyzed the data: EME JTT BSK VGF LPP. Contributed reagents/materials/analysis tools: VGF FR AJK NH HS WVK SR. Wrote the paper: EME JTT BSK VGF.","All authors have read the journals policy and the authors of this manuscript have the following competing interests: V.G.F. reported serving as chair of Merck’s V710 scientific advisory committee; receiving grant support and having grants pending from NIH, MedImmune, Forest/Cerexa, Pfizer, Merck, Advanced Liquid Logics, Theravance, Novartis, and Cubist; serving as a paid consultant for Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Contrafect; personal fees from Royalties (UpToDate), personal fees from Payment for development of educational presentations (Green Cross, Cubist, Cerexa, Durata, Theravance), and a patent pending on bacterial diagnostics. A.J.K. has received payments for lectures from BD Biosciences, Biomérieux, MSD Sharp & Dohme, imbach Gruppe SE, and ViiV Healthcare, and travel support from Janssen-Cilag. H.S. has received grants or research support from the Bundesministerium für Bildung und Forschung (BMBF), Germany, the German Center for Infection Research (DZIF), Basilea, Novartis and Pfizer, has been a consultant for Astellas, AstraZeneca, Basilea, Cubist, Novartis, Pfizer, Tetraphase, and The Medicines Company, and has received payments for lectures from MSD, Novartis and Pfizer. S.R. has received payments for lectures from Pfizer and MSD Sharp & Dohme, as well as travel support from Astellas and MSD Sharp & Dohme. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","11","Emily M Eichenberger","EME",13,TRUE,6,4,5,4,TRUE,TRUE,FALSE,0,NA,FALSE
